Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
HCPs can expand their impact by increasing awareness of the diverse causes of hearing loss and by actively connecting with both current and potential patients through community outreach and professional partnerships.
Researchers at Wake Forest University have developed a flexible, non-invasive hearing device that may offer an effective alternative to implantable aids and surgeries for treating conductive hearing loss.
The 2025 World Tinnitus Congress united global experts to explore cutting-edge research, treatments, and technological innovations in tinnitus care.
Interacoustics' Equinox Evo and Touch Keyboard provide an intuitive audiometric solution designed to enhance clinical workflows and patient engagement for audiologists.
Integrating audiometric testing through telehealth appointments with satellite offices provides audiologists with numerous benefits, including increased access to underserved areas, improved operational efficiency, cost-effective expansion, and enhanced patient convenience.